Oral News and Research

RSS

TLR1 plays a critical role in protecting the body from food-borne illnesses

A naturally occurring protein called TLR1 plays a critical role in protecting the body from illnesses caused by eating undercooked pork or drinking contaminated water, according to new research from the University of Southern California (USC).

11 Jul 2012

SRI International receives DoD grant to develop novel therapy for MS

The Department of Defense (DoD) has awarded SRI International a one-year grant to develop a novel therapy for multiple sclerosis (MS), an autoimmune nervous system disease that affects about 400,000 people in the United States and more than two million people worldwide. There is currently no cure for this disorder, which can impair vision and movement.

11 Jul 2012

Long-term study shows effectiveness of fissure sealing

Sealing pits and fissures with a resin-based material can arrest the progression of noncavitated dentinal occlusal caries, show results of a 36-month clinical trial.

10 Jul 2012

Herpes zoster vaccine recommendations questioned in patients on biologics

Administration of the live attenuated herpes zoster vaccine is not associated with an increased risk for shingles shortly after vaccination in patients receiving biologic treatments for immune-mediated diseases, researchers report in JAMA.

10 Jul 2012

AF care ‘inadequate’

Cardiology experts are supporting a call for greater attention to diagnosis and management of atrial fibrillation in primary care to prevent strokes.

10 Jul 2012

Phase III darexaban results revealed

The direct oral factor Xa inhibitor darexaban is effective for the prevention of venous thromboembolism in Japanese patients undergoing major abdominal surgery, researchers find.

10 Jul 2012

High-dose vitamin D recommended for over 65s

Meta-analysis findings support recommendations from the Institute of Medicine that people aged 65 years and older should routinely receive 800 IU of vitamin D per day.

10 Jul 2012

Kidney treatment could affect mouth health

Study results indicate a positive association between the type of treatment modality chronic kidney disease patients receive and the likelihood for them having periodontitis.

10 Jul 2012

Neuroprotective effects underpin fingolimod benefits in MS

Fingolimod therapy reduces inflammatory activity and tissue loss in the brains of patients with multiple sclerosis, shows further analysis of the FREEDOMS trial.

10 Jul 2012

Poor vaccine uptake blamed for polio rise in Pakistan, Afghanistan

The number of cases of poliomyelitis per year in Pakistan and Afghanistan has more than doubled since 2006 despite improvements in available vaccine efficacy, show study findings in The Lancet.

10 Jul 2012

Effective ketoprofen dose identified for pig endotoxins

Compared with tap water, treatment with ketoprofen significantly reduces the rectal temperature and total clinical scores among pigs challenged with the Escherichia coli endotoxin, report researchers.

10 Jul 2012

Self-management of anticoagulants in elderly could be beneficial

Elderly patients who self-manage their oral anticoagulant treatment have a comparable treatment-related quality of life to those who undergo routine care, and may even experience higher treatment satisfaction, researchers say.

10 Jul 2012

Iron supplementation decreases fatigue by almost 50% in nonanemic women

Iron supplementation reduced fatigue by almost 50% in women who are low in iron but not anemic, according to the results of a clinical trial published July 9 in CMAJ (Canadian Medical Association Journal).

10 Jul 2012

Enrollment complete in Lux Biosciences Luveniq Phase 3 study for non-infectious uveitis

Lux Biosciences, Inc. today announced the completion of patient enrollment in its Phase 3 clinical study of Luveniq (oral voclosporin) for the treatment of non-infectious uveitis. Lux Biosciences anticipates that data from the Phase 3 study will be available early in the first quarter of 2013.

9 Jul 2012

Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.

9 Jul 2012

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Inspiration Biopharmaceuticals, Inc. today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds.

9 Jul 2012

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Ampio announces results from Optina trial on DME

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), announced the significant results from their further analysis of its Optina trial on DME.

9 Jul 2012

More than 570 pioneering dentists assembled at MDL USA's World Dental Forum

Modern Dental Laboratory USA (MDL USA) assembled a group of 570 pioneering dentists from all over the world to come together at their second-annual World Dental Forum in Hong Kong and Shenzhen, China from May 31 to June 3, 2012.

8 Jul 2012